FOLH1 and prostate carcinoma: PET/CT imaging is increasingly used for targeted diagnostic imaging in prostate cancer (PCa), since radiopharmaceuticals labeled to the Prostate-specific Membrane Antigen (PSMA) were introduced 5 years ago [1–6].